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Hydroxychloroquine shortages among patients 
with systemic lupus erythematosus during the 
COVID-19 pandemic: experience of the 
Systemic Lupus International 
Collaborating Clinics
Early scientific and public enthusiasm for hydroxychloroquine 
(HCQ) as a potential therapy for COVID-19 has prompted 
over 100 registered trials to date, although its efficacy remains 
to be demonstrated.1 Unfortunately, accelerated demand for 
HCQ has the potential to diminish supplies for patients with 
systemic lupus erythematosus (SLE), which is worrisome due to 
the known risks of SLE flare after HCQ withdrawal.2 We previ-
ously reported that rheumatologists in most Canadian provinces 
observed HCQ shortages early in the COVID-19 pandemic.3 
However, data are lacking on the global experience with HCQ 
access during the pandemic, specifically in SLE.
On 4 May 2020, we distributed an electronic survey to 
the 42 Systemic Lupus Erythematosus International Collabo-
rating Clinics (SLICC) members affiliated with SLE referral 
centres (https:// sliccgroup. org), with reminders after 1 and 3 
weeks. Physicians were asked about experiences with HCQ 
shortages during the COVID-19 pandemic, and whether they 
had been contacted by patients and/or pharmacists regarding 
difficulties accessing HCQ. Physicians who answered ‘yes’ 
to the latter question were asked to estimate how many and 
what proportion of their patients with SLE were affected. We 
inquired about regional measures taken that exacerbated or 
helped mitigate HCQ shortages for patients with SLE (free 
text responses).
We received 31 responses (rate 74%) from 13 of 15 coun-
tries represented in SLICC, mostly from Europe (29%), the 
USA (26%) and Canada (23%). Over half (55%) reported either 
previous (39%) or current (16%) HCQ shortages among patients 
with SLE during the pandemic (see table 1). Two- thirds (65%) 
were contacted by patients and pharmacies regarding difficulties 
accessing HCQ. Seventeen provided estimates of the number and 
proportion of their patients affected, which corresponded to a 
median of 40 (IQR 15–90) patients per physician representing 
15% (IQR 5%–35%) of respective SLE populations. Seven physi-
cians noted that shortages resolved within 2–8 weeks. Members 
from four countries (Sweden, Denmark, Singapore, South Korea) 
reported no HCQ access issues among their patients.
Physicians identified regional factors contributing to HCQ 
shortages, including diversion of HCQ to hospitals (n=3), 
for clinical trials (n=2) or off- label empiric prescribing for 
COVID-19 (n=1).
Twenty- three (74%) reported system- level measures taken 
during the pandemic to preserve HCQ access for patients with 
SLE, which included limiting prescribing capabilities to specific 
specialties (n=9) or diagnoses (n=10) and limiting dispensed 
supply (n=3). Some restrictions may have inadvertently 
delayed HCQ access for patients with SLE, who had to wait 
for physicians to update diagnostic codes in medical records, 
confirm diagnoses with pharmacies or apply for waivers. In 
some cases, patients had to register for pharmacy dispensing 
programmes or were subjected to general dispensing restric-
tions. In Canada, the USA and the UK, patient and physician 
organisations advocated to health authorities for the rapid 
resolution of HCQ shortages.
Currently, there is no substitution for antimalarials in SLE. 
HCQ reduces disease flares,2 damage4 and mortality,5 with 
fewer adverse effects compared with glucocorticoids and 
immunosuppressants.6 Regardless of the ultimate efficacy 
of HCQ for COVID-19, preserving patients’ access to crit-
ical medications remains paramount. We observed that HCQ 
prescription restrictions were a common short- term strategy, 
although our cross- sectional survey was not intended to eval-
uate which mitigation strategies were most effective. Further-
more, physician estimates from single tertiary centres do not 
represent a comprehensive account of HCQ shortages or 
mitigation strategies and may not reflect the experience of an 
entire region or country.
According to this survey, HCQ access issues for patients 
with SLE occurred in multiple countries and continents during 
the COVID-19 pandemic. Because SLE can flare as little as 
2 weeks after HCQ cessation,2 further study of outcomes 
among patients who lost access to HCQ during the pandemic 
is warranted.
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Concerned about HCQ shortages, n
  Current 1 2 1 0 0 0 0 0 0 1 0 0 0
  Resolved 1 5 0 3 1 1 0 0 1 0 0 0 0
Physicians contacted by patients 
re: HCQ access issue, n
3 8 1 3 1 1 0 0 1 1 1 0 0
Estimated % of patients with SLE 
affected (range)
3%–5% 5%–40% 70% 0%–5% NR 20% – – 30% 50% 0%–1% – –
Regional mitigation strategies
Limiting authorised prescribers + + + + + + +
Limiting HCQ to specific 
diagnoses
+ + + + + + +




Hospital or pharmacies reserved 
supply for patients with SLE
+
*One respondent did not indicate country of origin and is not included in this table.
HCQ, hydroxychloroquine; NR, not reported; SLE, systemic lupus erythematosus.
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